ANZTCT consensus position statement on ruxolitinib in steroid-refractory acute and chronic graft-versus-host disease.

Nada HamadIan BilmonLynette CheeAndrea HendenAnna JohnstonDuncan PurtillAshish BajelSiok-Keen TeyDavid YeungTheresa ColeClinton LewisJason Butler

Published in: Internal medicine journal (2023)

This position paper provides an overview of the assessment and management of both acute and chronic graft-versus-host disease (GvHD). There is a focus on the use of ruxolitinib, a selective inhibitor of Janus kinase (JAK)1 and JAK2, for the treatment of corticosteroid-refractory and corticosteroid-dependent GvHD.

Keyphrases

liver failure
drug induced
respiratory failure
allogeneic hematopoietic stem cell transplantation
aortic dissection
hepatitis b virus
acute myeloid leukemia
protein kinase
intensive care unit
extracorporeal membrane oxygenation
replacement therapy